+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Skin Cancer Drugs Global Market Report 2022, Type, End Users, Drug Class

  • PDF Icon

    Report

  • 175 Pages
  • March 2022
  • Region: Global
  • The Business Research Company
  • ID: 5559828
Skin Cancer Drugs Global Market Report 2022 provides strategists, marketers and senior management with the critical information they need to assess the global skin cancer drugs market as it emerges from the Covid 19 shut down.



Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 12+ geographies.
  • Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market research findings.
  • Benchmark performance against key competitors.
  • Utilize the relationships between key data sets for superior strategizing.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis

Description:


Where is the largest and fastest growing market for the skin cancer drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The Skin Cancer Drugs Market Global Report answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

  • The Market Characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, the impact of the Covid 19 virus and forecasting its recovery.
  • Market segmentations break down market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the impact and recovery trajectory of Covid 19 for all regions, key developed countries and major emerging markets.
  • Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope


Markets Covered:
1) By Type: Actinic Keratoses (AK); Basal cell carcinoma (BCC); Squamous cell carcinoma (SCC); Melanoma
2) By End Users: Hospitals; Cancer Research Centers; Clinics
3) By Drug Class: Chemotherapy; Immunotherapy; Targeted Agents & Other Drugs

Companies Mentioned: Novartis AG; Bristol Myers Squibb; Eli Lilly; Meda; Sun Pharmaceutical Industries Ltd.

Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time Series: Five years historic and ten years forecast.

Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.


This product will be delivered within 1-3 business days.
Frequently Asked Questions about the Global Skin Cancer Drugs Market

What is the estimated value of the Global Skin Cancer Drugs Market?

The Global Skin Cancer Drugs Market was estimated to be valued at $3.06 billion in 2022.

What is the growth rate of the Global Skin Cancer Drugs Market?

The growth rate of the Global Skin Cancer Drugs Market is 15.2%, with an estimated value of $5.39 billion by 2026.

What is the forecasted size of the Global Skin Cancer Drugs Market?

The Global Skin Cancer Drugs Market is estimated to be worth $5.39 billion by 2026.

Who are the key companies in the Global Skin Cancer Drugs Market?

Key companies in the Global Skin Cancer Drugs Market include Novartis AG, Bristol Myers Squibb, Eli Lilly, Meda, Sun Pharmaceutical Industries Ltd., Roche, Aqua Pharmaceuticals, Bausch Health and Pfizer Inc..

Table of Contents

1. Executive Summary2. Skin Cancer Drugs Market Characteristics3. Skin Cancer Drugs Market Trends And Strategies4. Impact Of COVID-19 On Skin Cancer Drugs
5. Skin Cancer Drugs Market Size And Growth
5.1. Global Skin Cancer Drugs Historic Market, 2016-2021, $ Billion
5.1.1. Drivers Of The Market
5.1.2. Restraints On The Market
5.2. Global Skin Cancer Drugs Forecast Market, 2021-2026F, 2031F, $ Billion
5.2.1. Drivers Of The Market
5.2.2. Restraints On the Market
6. Skin Cancer Drugs Market Segmentation
6.1. Global Skin Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Actinic Keratoses (AK)
  • Basal cell carcinoma (BCC)
  • Squamous cell carcinoma (SCC)
  • Melanoma
6.2. Global Skin Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Hospitals
  • Cancer Research Centers
  • Clinics
6.3. Global Skin Cancer Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Chemotherapy
  • Immunotherapy
  • Targeted Agents & Other Drugs

7. Skin Cancer Drugs Market Regional And Country Analysis
7.1. Global Skin Cancer Drugs Market, Split By Region, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
7.2. Global Skin Cancer Drugs Market, Split By Country, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
8. Asia-Pacific Skin Cancer Drugs Market
8.1. Asia-Pacific Skin Cancer Drugs Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Skin Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
8.3. Asia-Pacific Skin Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
8.4. Asia-Pacific Skin Cancer Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
9. China Skin Cancer Drugs Market
9.1. China Skin Cancer Drugs Market Overview
9.2. China Skin Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F,$ Billion
9.3. China Skin Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2016-2021, 2021-2026F, 2031F,$ Billion
9.4. China Skin Cancer Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F,$ Billion
10. India Skin Cancer Drugs Market
10.1. India Skin Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
10.2. India Skin Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
10.3. India Skin Cancer Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
11. Japan Skin Cancer Drugs Market
11.1. Japan Skin Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
11.2. Japan Skin Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
11.3. Japan Skin Cancer Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
12. Australia Skin Cancer Drugs Market
12.1. Australia Skin Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
12.2. Australia Skin Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
12.3. Australia Skin Cancer Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
13. Indonesia Skin Cancer Drugs Market
13.1. Indonesia Skin Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
13.2. Indonesia Skin Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
13.3. Indonesia Skin Cancer Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
14. South Korea Skin Cancer Drugs Market
14.1. South Korea Skin Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
14.2. South Korea Skin Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
14.3. South Korea Skin Cancer Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
15. Western Europe Skin Cancer Drugs Market
15.1. Western Europe Skin Cancer Drugs Market Overview
15.2. Western Europe Skin Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
15.3. Western Europe Skin Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
15.4. Western Europe Skin Cancer Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
16. UK Skin Cancer Drugs Market
16.1. UK Skin Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
16.2. UK Skin Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
16.3. UK Skin Cancer Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
17. Germany Skin Cancer Drugs Market
17.1. Germany Skin Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
17.2. Germany Skin Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
17.3. Germany Skin Cancer Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
18. France Skin Cancer Drugs Market
18.5. France Skin Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
18.6. France Skin Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
18.7. France Skin Cancer Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
19. Eastern Europe Skin Cancer Drugs Market
19.1. Eastern Europe Skin Cancer Drugs Market Overview
19.2. Eastern Europe Skin Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
19.3. Eastern Europe Skin Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
19.4. Eastern Europe Skin Cancer Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
20. Russia Skin Cancer Drugs Market
20.1. Russia Skin Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
20.2. Russia Skin Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
20.3. Russia Skin Cancer Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
21. North America Skin Cancer Drugs Market
21.1. North America Skin Cancer Drugs Market Overview
21.2. North America Skin Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
21.3. North America Skin Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
21.4. North America Skin Cancer Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
22. USA Skin Cancer Drugs Market
22.1. USA Skin Cancer Drugs Market Overview
22.2. USA Skin Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
22.3. USA Skin Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
22.4. USA Skin Cancer Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
23. South America Skin Cancer Drugs Market
23.1. South America Skin Cancer Drugs Market Overview
23.2. South America Skin Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
23.3. South America Skin Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
23.4. South America Skin Cancer Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
24. Brazil Skin Cancer Drugs Market
24.1. Brazil Skin Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
24.2. Brazil Skin Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
24.3. Brazil Skin Cancer Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
25. Middle East Skin Cancer Drugs Market
25.1. Middle East Skin Cancer Drugs Market Overview
25.2. Middle East Skin Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
25.3. Middle East Skin Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
25.4. Middle East Skin Cancer Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
26. Africa Skin Cancer Drugs Market
26.1. Africa Skin Cancer Drugs Market Overview
26.2. Africa Skin Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
26.3. Africa Skin Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
26.4. Africa Skin Cancer Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
27. Skin Cancer Drugs Market Competitive Landscape And Company Profiles
27.1. Skin Cancer Drugs Market Competitive Landscape
27.2. Skin Cancer Drugs Market Company Profiles
27.2.1. Novartis AG
27.2.1.1. Overview
27.2.1.2. Products and Services
27.2.1.3. Strategy
27.2.1.4. Financial Performance
27.2.2. Bristol Myers Squibb
27.2.2.1. Overview
27.2.2.2. Products and Services
27.2.2.3. Strategy
27.2.2.4. Financial Performance
27.2.3. Eli Lilly
27.2.3.1. Overview
27.2.3.2. Products and Services
27.2.3.3. Strategy
27.2.3.4. Financial Performance
27.2.4. Meda
27.2.4.1. Overview
27.2.4.2. Products and Services
27.2.4.3. Strategy
27.2.4.4. Financial Performance
27.2.5. Sun Pharmaceutical Industries Ltd
27.2.5.1. Overview
27.2.5.2. Products and Services
27.2.5.3. Strategy
27.2.5.4. Financial Performance
28. Skin Cancer Drugs Pipeline Analysis29. Key Mergers And Acquisitions In The Skin Cancer Drugs Market30. Skin Cancer Drugs Market Future Outlook and Potential Analysis
31. Appendix
31.1. Abbreviations
31.2. Currencies
31.3. Research Inquiries
31.4. About the Publisher
31.5. Copyright And Disclaimer

Executive Summary

Major players in the skin cancer drugs market are Novartis AG, Bristol Myers Squibb, Eli Lilly, Meda, Sun Pharmaceutical Industries Ltd, Roche, Aqua Pharmaceuticals, Bausch Health, GlaxoSmithKline PLC and Pfizer Inc.

The global skin cancer drugs market is expected to grow from $2.62 billion in 2021 to $3.06 billion in 2022 at a compound annual growth rate (CAGR) of 17.0%. The growth is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $5.39 billion in 2026 at a CAGR of 15.2%.

The skin cancer drugs market consists of sales of skin cancer drugs. Skin Cancer is an unrestricted growth of abnormal skin cells that lead skin cells to proliferate rapidly and form malignant tumors. Skin cancer can be of various types including actinic keratoses, basal cell carcinoma, squamous cell carcinoma or melanoma. Examples of skin cancer drug include 5-FU, Aldara and Efudex.

The main types of skin cancer drugs are actinic keratoses (AK), basal cell carcinoma (BCC), squamous cell carcinoma (SCC) and melanoma. Actinic keratoses is a broad, rough skin patch which can turn cancerous. It commonly appears on sun-exposed regions such the face, scalp, backs of the hands, and chest. It is especially common in fair-skinned persons. Solar keratosis and senile keratosis are two terms for the same condition. The different classes of drugs include chemotherapy, immunotherapy, targeted agents & other drugs and is used in various sectors such as hospitals, cancer research centers, clinics.

North America is the largest region in the skin cancer drugs market in 2021. Middle East is expected to be the fastest growing region in the forecast period. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Significant rise in prevalence of skin cancer is driving the demand for the drugs for Skin Cancer. To treat such high cases of skin cancer, more number of new innovative skin cancer drugs is being manufactured. According to the American Academy Of Dermatology, in 2019, there were 192,310 new cases of Melanoma type skin cancer. Additionally, non-invasive type skin cancer count could rise to 95,830 and 96,480 invasive skin cancer could be diagnosed in US in 2019. According to the American Academy Of Dermatology, each year roughly around 3 million Americans get diagnosed by skin cancer. This is boosting the demand for skin cancer drugs and thus driving the market.

Increasing use of biologics and targeted therapies is acting as a restraint in the skin cancer drugs market. The targeted therapies drugs targets melanoma cells only. The chemical drugs attack any fast-dividing cells while targeted therapies only attack the skin cancer causing melanoma cells. Thus, doctors are preferring targeted therapies to treat skin cancer. This is expected to affect the sales of conventional chemical skin cancer drugs and limit the growth of the market going forward.

Companies in the Skin Cancer Market are increasingly looking for Strategic Alliances with other companies in the market. Strategic Alliance would help companies to enhance their R&D capability, expedite the development process of new drugs and reinforce competitive position in the market. For example, Leo Pharma has formed a strategic alliance with PellePharm, to develop a drug to treat a very rare form of skin cancer called Gorlin syndrome. MorphoSys and LEO Pharma strategically worked together to develop antibodies pertaining to the treatment of skin cancer. Pfizer had entered into a strategic alliance with Merck KGaA to manufacture an innovative drug pertaining to skin cancer.

The European Medicines Agency (EMA) is the regulatory body that evaluates and supervises the production and sales of medicines for safety and benefit of the customer, in the European Union Region. The manufacturers of skin cancer drugs and all other drugs need to comply with manufacturing practices specified by the EMA. EMA also regulates and supervises the drug quality, check for the intended use of the drug and whether the drug is meeting the requirement of clinical trial. EMA also educates the patients regarding the risks associated in taking skin cancer drugs such as Tafinlar and Opdivo, what are the safety measures that are needed to be taken while consuming the drug, benefits of the drug and all other relevant information pertaining to such drugs.

In April 2019, Bristol-Myers Squibb acquired Celgene for $74 billion. This acquisition would help Bristol-Myers Squibb to widen its portfolio of drug in skin cancer market. This acquisition would also help Bristol-Myers Squibb to expedite the development of new innovative drugs which are in the early stages of drug pipeline. Celgene is an innovative biotechnology company that manufactures and develops cancer drugs. Celgene was founded in 1986 and is headquartered at Summit, New Jersey, United States.

The countries covered in the skin cancer drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Novartis AG
  • Bristol Myers Squibb
  • Eli Lilly
  • Meda
  • Sun Pharmaceutical Industries Ltd.
  • Roche
  • Aqua Pharmaceuticals
  • Bausch Health
  • GlaxoSmithKline PLC.
  • Pfizer Inc.
  • AstraZeneca
  • Sanofi SA
  • Qiagen
  • Boehringer Ingelheim
  • Elekta AB
  • Varian Medical Systems
  • Valeant Pharmaceuticals
  • Mylan N.V
  • Merck & Co.
  • Cannabis Science Inc.
  • Cellceutix Corp.
  • LEO Pharma A/S
  • Daiichi Sankyo
  • iCAD Inc.
  • AB Sciences

Methodology

Loading
LOADING...